GSK News and Press, GlaxoSmithKline PLC

2026-03-11 16:22:24 ET GSK plc (GSK) Barclays 28th Annual Global Healthcare Conference March 11, 2026 11:30 AM EDT... Read the full article on Seeking Alpha For further details see: GSK plc (GSK) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

2026-03-10 15:44:56 ET Introduction Read the full article on Seeking Alpha For further details see: Moderna: Pipeline Hope Won't Pay The Bills

2026-03-10 10:53:45 ET More on GSK GSK: Post-Pivot Buoyancy Set To Continue After Strong 2025 (Upgrade) GSK plc 2025 Q4 - Results - Earnings Call Presentation GSK plc (GSK) Q4 2025 Earnings Call Transcript Tylenol use in pregnancy fell after Trump’s au...

2026-03-07 07:41:45 ET More on Pfizer, Johnson & Johnson, etc. Pfizer: Obesity Hype And Vaccine Policy Shocks The Sun Will Shine On Moderna Again - Initiating With A Buy Why Moderna's $950M Patent Bill Is A Small Price For Pipeline Freedom J&J subsidi...

2026-03-06 14:58:14 ET More on Kenvue, GSK Kenvue: Out Of Favor Then, Under Pressure Now GSK: Post-Pivot Buoyancy Set To Continue After Strong 2025 (Upgrade) Kimberly-Clark: After The Kenvue Merger Vote, Ready To Rumble? CDC acting director calls for measles ...

2026-03-06 10:45:02 ET More on Pfizer, Merck, etc. Pfizer: Obesity Hype And Vaccine Policy Shocks AbbVie: Stabilizes Near $233 While Testing Resistance Pfizer's Portfolio Renewal In Progress - High Yields For The Patient China approves Pfizer’s GLP-1 d...

2026-03-05 16:02:27 ET More on dividend ETFs SCHD: When AI Hype Fades And Geopolitics Bite Vanguard Dividend Appreciation Index Fund ETF: Quality Discipline For Turbulent Times SCHD: Aren't You Glad You Didn't Sell? Yield strategies shine: Dividend funds deli...

2026-03-03 08:33:21 ET More on Merck, GSK Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie Merck: Why Investors Should Remain Bullish Despite Patent Risks GSK: Post-Pivot Buoyancy Set To Continue After Strong 2025 (Upgrade) M...

2026-02-27 02:54:16 ET Shares of antisense therapy concern Ionis Pharmaceuticals, Inc. ( IONS ) have rallied strongly since its familial chylomicronemia syndrome med Tryngolza (olezarsen) bore strong data treating severe hypertriglyceridemia. Announced in September 2025, the res...

2026-02-26 13:35:52 ET More on leading drugmakers Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie Johnson & Johnson: Strong Run May Be Ending (Rating Downgrade) Merck: Why Investors Should Remain Bullish Despite Patent Risks ...